Friday, September 25, 2020
Home Partner Profiles Regenerative gene therapies with the potential to transform respiratory medicine

Regenerative gene therapies with the potential to transform respiratory medicine

Discover OmniSpirant, the innovative company of experts in the fields of pulmonary gene therapies, cell-free regenerative medicine and respiratory medicine.

OmniSpirant is an Irish company that is developing an inhaled gene therapy platform based on regenerative stem cell exosomes. Their patent pending surface engineered and bioengineered stem cell exosomes platform will initially be used to develop a first in class regenerative gene therapy for Cystic Fibrosis.

Delivering a variety of regenerative gene therapies

The mucus penetrating exosomes combine cell-free regenerative medicine and gene therapy in a nanosized package with the potential to make a huge therapeutic impact. These tiny exosomes can effectively delivery a variety of gene therapy cargoes in a platform which has transformative potential to treat many other lung diseases.

OmniSpirant believes their technology has the potential to positively impact the lives of millions of patients. By creating a bold new approach to treat currently incurable respiratory diseases, their advanced therapies intersect the cell-free regenerative medicine and gene therapy fields with the hope of treating devastating lung diseases.

OmniSpirant Limited was founded by Gerry McCauley who is the inventor of OmniSpirant’s inhaled engineered exosome technology.

McCauley has extensive commercial knowledge and has built an international network of experts in the fields of regenerative medicine, gene therapy and respiratory drug delivery.

Further investment to transform respiratory medicine

OmniSpirant are currently seeking seed investment to fund further CF preclinical studies and initiate programs with promising breakthrough potential to treat Lung Adenocarcinoma and Chronic Obstructive Pulmonary Disease (COPD). Proof of concept studies to develop a novel regenerative gene therapy for COPD have recently commenced. OmniSpirant has partnered with the Celtic Advanced Life Science Innovation Network (CALIN), an EU INTERREG operation, to carry out this COPD research with breakthrough potential. The CALIN network has strengthened existing collaborations with the regenerative medicines institute at NUI Galway and made new connections with experts at Cardiff University.

This innovative COPD therapy could for the first time effectively treat this EU priority disease which kills over 300,000 EU citizens every year.

OmniSpirant Limited has received funding from the European Union’s Horizon 2020 research and innovation programme under SME Instrument grant agreement 855463_ReSpire.

  • Stem cell bioengineering for production of regenerative exosome gene therapies
  • Extracellular vesicle/exosome surface engineering
  • Respiratory medicine and drug delivery
  • MicroRNA modulation for gene therapy
  • mRNA gene therapy
  • Cystic Fibrosis
  • Lung Cancer, Idiopathic Pulmonary Fibrosis and COPD and associated gene networks/pathways

Profile in Health Europa Quarterly – Issue 9
Profile in Health Europa Quarterly – Issue 12
Profile in Health Europa Quarterly – Issue 14

Pin It on Pinterest